Leqvio (inclisiran) Letter of Medical Necessity
Leqvio (inclisiran) is a first-in-class siRNA PCSK9 inhibitor dosed just twice yearly after initiation, offering a distinct adherence advantage over monthly monoclonal antibody PCSK9 inhibitors. Prior authorization requires documentation of prior statin and ezetimibe trials, and step-therapy with a PCSK9 monoclonal antibody is commonly required by payers.
FDA-Approved Indications
- ● primary hyperlipidemia or mixed dyslipidemia as an adjunct to diet and maximally tolerated statin therapy (adults with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia)
Why Leqvio Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Maximally tolerated statin not documented or statin intolerance not established
- 2. LDL-C goal and current LDL-C level not on file
- 3. Monoclonal antibody PCSK9 inhibitor (Repatha, Praluent) not tried first (step therapy)
- 4. Cardiovascular disease or HeFH diagnosis not confirmed
- 5. Ezetimibe trial not documented
- 6. Administered in office — Part B billing code (J3101) not recognized by MA plan
What to Include in a Leqvio Letter of Medical Necessity
Document ASCVD diagnosis (coronary artery disease, stroke, peripheral artery disease) or HeFH diagnosis, fasting lipid panel with current LDL-C and on-treatment LDL-C goal, current statin and dose with documented maximum tolerated intensity, ezetimibe trial with response, prior PCSK9 monoclonal antibody trial (Repatha or Praluent) with outcome if step therapy applies, and rationale for siRNA-based therapy — particularly adherence, injection frequency preference, or formulary access.
Key clinical evidence to cite:
- ✓ ORION-10 and ORION-11 Phase 3 trials — ~50% LDL-C reduction from baseline at Day 510
- ✓ ORION-4 outcomes trial — MACE reduction in ASCVD patients (ongoing, interim data published)
- ✓ Twice-yearly dosing (day 1, day 90, then every 6 months) — adherence advantage over monthly injectables
Relevant guidelines:
- 📖 ACC/AHA 2022 Cholesterol Guideline Update
- 📖 ACC Expert Consensus Decision Pathway for PCSK9 Inhibitors
- 📖 NLA Recommendations for ASCVD Risk Management
Leqvio Prior Authorization Criteria
Standard criteria across major US payers for Leqvio. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Monoclonal antibody PCSK9 inhibitor (Repatha, Praluent) not tried first (step therapy)
- → Ezetimibe trial not documented
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Leqvio
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Leqvio Prior Authorization FAQ
Why was my Leqvio prior authorization denied?
The most common denial reasons for Leqvio are: Maximally tolerated statin not documented or statin intolerance not established; LDL-C goal and current LDL-C level not on file; Monoclonal antibody PCSK9 inhibitor (Repatha, Praluent) not tried first (step therapy); Cardiovascular disease or HeFH diagnosis not confirmed; Ezetimibe trial not documented; Administered in office — Part B billing code (J3101) not recognized by MA plan.
What should a Leqvio Letter of Medical Necessity include?
Document ASCVD diagnosis (coronary artery disease, stroke, peripheral artery disease) or HeFH diagnosis, fasting lipid panel with current LDL-C and on-treatment LDL-C goal, current statin and dose with documented maximum tolerated intensity, ezetimibe trial with response, prior PCSK9 monoclonal antibody trial (Repatha or Praluent) with outcome if step therapy applies, and rationale for siRNA-based therapy — particularly adherence, injection frequency preference, or formulary access.
Which payers cover Leqvio?
Leqvio is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Humana, Medicare Part B (physician-administered), though formulary tier and prior authorization criteria vary.